Shamburg News · 8-K filed Nov 13, 2026, 7:05 AM EST
Tvardi Therapeutics Reports Third Quarter 2026 Results and Provides Business Update
TVRD · Tvardi Therapeutics, Inc.
- Earnings
- Materiality: high
Tvardi Therapeutics reported a net loss of $6.1 million, or $(0.48) per share, for the three months ended September 30, 2026, compared with a net loss of $5.5 million, or $(0.59) per share, a year earlier. Research and development expenses were $4.5 million and general and administrative expenses were $1.9 million for the quarter. Cash and cash equivalents were $22.3 million as of September 30, 2026, and the company expects existing cash to fund operations into the third quarter of 2027.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001104659-26-126507.
Written from the filing by Shamburg Markets. Figures are as reported by the company.